Cannabis Report
Home > Boards > US OTC > Medical - Drugs >

ViaDerma Inc. (VDRM)

Add VDRM Price Alert      Hide Sticky   Hide Intro
Moderator: SchlumpyStock-Picker, Clonefan, Chicagojosh, ResidualRevenue
Search This Board: 
Last Post: 5/27/2018 3:36:32 PM - Followers: 504 - Board type: Free - Posts Today: 1



A Division of ViaDerma, Inc. , A Public Company.

Breakthrough Rapid Delivery of Nutrients and Medicines

ViaDerma, Inc. is a biotechnology licensing company committed to bringing new products quickly to the pharmaceutical industry through innovative research & development. ViaDerma licenses products in fields of medicine ranging from infectious diseases to stem-cell therapy.

About Our Products

Proprietary and Trade Secret Mechanism of Action

ViaDerma's proprietary transdermal delivery system allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.

The technology allows transfer of chemicals through the stratum corneum (outer layer of skin) with a diffusion constant which is 10,000 times higher than the diffusion constant which characterizes water movement through the stratum corneum.

This enables ViaDerma to pair almost any active ingredient with the technology and provide rapid transport of the medicine right to the site of action.

The first product is a broad spectrum tetracycline-based topical antibiotic is the only antibiotic in the world that kills bacteria both a physical and a chemical mechanism. All known antibiotics (other than ours) primarily use only a chemical mechanism of kill. The physical mechanism of kill is a key feature of what we call Rapid Active Ingredient Delivery System (RAIDS). One result of RAIDS is that tetracycline is carried in higher concentrations, more quickly, to and through the cell walls, where the tetracycline can become more effective than if conventional antibiotics were used. Conventional antibiotics require more time (usually prescribed for 5 to 7 days for best results), whereas our tetracycline-based products usually produce desirable results in 24 hours (or less) because of the RAIDS effect.

Skin Layer Organization

A second important result of RAIDS is that the topical antibiotic kills all harmful Gram positive and Gram negative bacteria that have been available for testing. We believe this is the world’s strongest broad-spectrum topical antibiotic available.

The potential commercial impact is immense. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their response to a chemical threat, but it takes numerous generations for bacteria to grow a new kind of cell wall structure to respond to a physical threat.

Our novel approach to overcome drug resistance of antibiotics is designed to sustain the effectiveness of antibiotics and other topical drugs for many years. This gives new topical drug products a longer useful lifetime and therefore more commercial value. This technology, when licensed to larger pharmaceutical companies, may provide stronger incentive for the discovery and development of new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to the uncertain new-drug commercial lifetime which is diminished when bacteria develop immunity to that drug.

In addition the technology can be licensed to other companies to convert existing oral drugs to transdermal medications extending the profitably of the existing drug.


Available at ....

ViaDerma Licensing FaceBook page at...


Vitastem treats Acne, Burns, Eczema, Infections, Psoriasis and Wounds

We are developing products in the following fields of use;

Topical antibiotics

Treats all types of bacteria including MRSA, VRE and other flesh eating bacteria. Fights drug resistant bacteria. $6B/year global market.

  • Estimated Global prevalence rate of all types of bacterial infection including pets: 2 Billion.
    Estimated Global prevalence rate of MRSA: 140 million.
Topical toenail antifungal

Onychomycosis, a fungal infection of the toenails, is a major health problem. It is estimated that there are in excess of 40 million sufferers with this condition in the USA. It is a problem throughout the world. A recent European study showed that the prevalence of Onychomycosis may be as high as 26.9%. Fungal resistance can occur when the oral antifungal agents are used on a long-term basis. Topically applied antifungal drugs may work somewhat better adjunctive to surgical removal or chemical dissolution of the nail plate. Yet, this often ineffective and traumatic procedure leaves the subject without a nail for months at risk for re-infection. Given the limitations of current treatment options in this $3B market, there is a great need for a simple, nontoxic and effective alternative treatment. Estimated Global prevalence rate: 140 million.

Anti-viral formula

Treats symptoms of Influenza which is a$4B/ year global market: Common

  • Estimated Global prevalence rate of Influenza: 355-1065 million.
    Estimated Global prevalence rate of “Bird Flu”: Very rare, about 500 cases.
    Estimated Global prevalence rate of “Swine Flu”: 1420 million were infected in 2009
Wound care

Diabetic foot wounds.

  • Diabetic foot Ulcers; $1.5B/year global market. 12 million people per year

We are currently in discussions with companies in Australia & New Zealand, India, China, and West Africa.


Contact Details

ViaDerma's global headquarters is located at

4640 Admiralty Way, Ste 500

Marina Del Rey, CA 90292

Phone: 310-496-5744





CBD Product launch!!!  

Initial order of 1,000 units sold into Canada have SOLD OUT!


Per 3/8/18 PR: ViaDerma’s technology is currently being used in Elixr Cannabis products; Topical Balm, Topical Serum and Topical Spray. Sales have begun in Canada.

Per 12/7/17 PR:  The Company has signed an MOU and will start production of its Patent Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent #62466209, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent # 62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinary uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. 

Per 1/23/18 PR:  The Company has also a licensing and distribution agreement in place with its Canadian partners to produce a CBD Topical Serum, which has a 92% absorption rate powered by ViaDerma's Patent Pending Dual Carrier Technology. The CBD and Terpene profile (enriched with specific essential oils and vitamins C, and D) is crafted to alleviate Chronic Dry Skin, Psoriasis, Eczema, Rosacea, and many other skin conditions. The serum has anti-inflammatory, anti-bacterial, and chronic pain relief properties that are absorbed by the skin and provide overall healing benefits. Sales are expected to begin in the first quarter of 2018 and are projected to generate approximately $2 million annual revenues.

The Patented Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2018.

What is CBD

CBD is a compound found in the Cannabis family of plants such as hemp. CBD is combined into our topical body care products like Elixr's Topical Balm, Serum, and  Spray.

CBD in Skin Care

CBD is an antioxidant. Antioxidants protect our skin from damaging exposure to smoke, UV rays,  and environmental pollutants. Cannabinoid receptors are located all throughout the skin, Topical CBD products interact with those receptors resulting homeostasis and healing. Studies show that CBD can help treat an array of skin conditions such as eczema, psoriasis, rosacea, and acne.

Dual Carrier Technology

Developed by a British Doctor and an American Pharmaceutical Company. Our Topical Products are formulated using Viaderma Pharmaceutical's Patent Pending Dual Carrier Technology. CBD is formulated into the carrier solution. This solution is then mixed with the professionally crafted skin care product using critically Essential Oils to maximize skin health care regime.


Elixr Hemp CBD Product Line


Our Elixr Hemp CBD Product line has a CBD Absorption Rate of 92% powered by Viaderma Pharmaceutical’s Patent Pending Dual Carrier Technology. Elixr Cannabis has the exclusive global rights to this groundbreaking technology combined with any Cannabinoids. Our products are second to none due to this independent laboratory tested high absorption rate combined with Elixr’s CDB profile.

Our CBD and Terpene profile, enriched with specific Essential Oils, Vitamin C, and Vitamin D, is crafted to alleviate Chronic Dry Skin, Psoriasis, Eczema, Rosacea, and many other skin conditions. CBD is known to have Anti-Inflammatory, Anti-Oxidant, and Anti-Aging properties that absorbs into the skin and provides overall healing benefits.

All our products are proudly Cruelty-free, 100% Toxin-free, Sodium Lauryl Sulfate free, Phthalate free, Parabens free, Petrochemicals free, Triclosan-free, Diethanolamine free and best of all, are handcrafted in Victoria, BC.

Essential Oils of Cypress, Frankincense, and Geranium


Essential Oils of Mint and Van

Topical S

Essential Oils of Lavender and Yarr


"What is Intellectual Property?"
- A Publication by the World Intellectual Property Organization -

2014 Provisional TBD TBD Is this referenced patent application an expired mmj provisional app from 2014? Otiko hasn't explained what happened here. BIOGENX 87290961 641 - Non-Final Action
2016  Patent App TBD TBD "its proprietary innovative transdermal delivery system" VITASTEM 87227123 681 - Publication/Issue Review Complete
2017 "Cannabis Provisional Patent"
(Incorrect Term)
62466209  Was this filed to replace the expired provisional cannabis app from 2014?      
2017 "enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses" 62433964 Is this related to the Viabecline product developed by the Phillips Company using their patent?      
Business Name Owner Registered Otiko's Role
19772 Trident Lane
Huntington Beach, CA 92646
Garrett Adams NV
First registered 12.14.16
Co-owns BIOGENX Trademark - Percent of BIOGENX business owned is unknown
NOTE: The news of BIOGENX as distributor did not reveal Otiko's ownership role.
Chemo-Pharma, Ltd  TBD No result from search
in Canada, England & India
Coast to Coast Podiatry, Inc.
6648 Reseda Blvd
Reseda, CA 91335
 First Registered 06.14.11
Updated 07.13.16
 Otiko states he is "Minority Owner" in his 12.09.16 Video Interview.
He is the named CEO, CFO, Secretary.  He was also sole director until filing of July 2016.
Sole Director is now his wife, Ekaterina Otiko.  Is Ekaterina the majority owner?
NOTE: The news of Coast to Coast as a distributor did not disclose Otiko's ownership role.






5/18/18 -

5/15/18 -

4/24/18 -

 4/2/18 -

3/8/18 -

3/2/18 -

2/26/18 -

2/6/18 -

1/23/18 -

12/7/17 -

11/21/17 - ViaDerma, Inc. is Granted Approval to sell VitaStem(TM) its FDA Registered Topical Antibiotic on and Expands Testing into Major US Hospital Chains to Ramp Up Domestic Sales & Begins Production of New Products

10/19/17 - ViaDerma, Inc. Commences Distribution of VitaStem(TM), its FDA Registered Topical Antibiotic, and Looks to Expand its Partnership with Biogenx 

09/08/17 - ViaDerma, Inc. Eyes Deal to Place its Patent Pending MMJ Technology into 400 Canadian Retail Stores and an on-line store via the Web, through its Management, Marketing and Distribution Partner in Canada

08/18/2017 - ViaDerma, Inc. Set to Begin Sales of its FDA Registered Topical Antibiotic in September with Initial Orders from Japan

06/27/2017- Viaderma, Inc Receives National Drug Code (NDC) from the FDA for Prolayed, It's New OTC Drug for Premature Ejaculation For Men

06/12/17 - ViaDerma, Inc. Commences First Manufacturing Run And Will Meet the 2nd Quarter Product Distribution Milestone  

05/15/17 - Viaderma, Inc. Recevies Positive Results On Phase I Testing In Canada With Its Proprietary THC delivery and moves to Phase II Trials and Development Of New Products With Its MMJ Technologies 

05/03/17 - ViaDerma, Inc. Will Vigorously Defend The Company's Patents, Product Line, and its Shareholders from current complaint against the company 

04/19/17 - ViaDerma, Inc. Announces its President, Dr. Christopher Otiko's Abstract was Well Received at the DFCON Conference as the Company Completes Final Testing for its FDA Registered Viabecline for Manufacturing in the Next Several Weeks

04/05/17 - ViaDerma, Inc. Enters the Sexual Dysfunction Market & Files with the Food and Drug Administration (FDA) for a New OTC Drug to Conquer Premature Ejaculation for Men

03/20/17 - ViaDerma Receives Provisional Patent Numbers for Its FDA Registered Viabecline and Cannabis Technologies, and Seeks to Distribute its Products with a Management, Marketing and Distribution Company in Canada to Approved International Cannabis Countries

03/08/17 - ViaDerma, Inc. Hires Product Rollout Expert to Manage Quality Control Labeling, Marketing and Distribution of its Go to Market Product Line Launch

02/15/17 - ViaDerma, Inc. Looks to File Additional Patents & License New Products for its (MMJ) Medical Marijuana Patent Pending Delivery Technology with Licensed Dispensaries

02/08/17 - Dr. Chris Ayo Otiko, President of ViaDerma, Inc., is selected to write an article "Healing Diabetic Ulcers with a New Topical Antibiotic Ointment" for the Journal of Diabetes
Science and Technology, a leading US Publication for Diabetes

02/03/17 - ViaDerma, Inc. Targets Online Sales, Wound Care Centers and Distribution Companies for its Viabecline Product Launch, the First Viabecline Orders Set for Q2-2017,
also  Onychomycosis Clinical Studies Show Significant Results

01/11/17 - ViaDerma, Inc's CEO Files New Patent Application, Signs Two Licensing Deals, Locates Product Manufacturers in the US & Abroad, and Plans to add over 500 Affiliates Selling
Viabecline Through Established Online Distribution Networks in 2017

12/09/16 - Video with Dr. Otiko by Jasyn Blair of Uptick Newswire - Notes
Cannabis Report
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#37340  Sticky Note Important news about the VDRM board... SchlumpyStock-Picker 05/16/18 11:06:47 AM
#37035  Sticky Note ViaDerma, Inc. Enters into a $250,000 Initial Sales Chicagojosh 04/26/18 10:04:58 AM
#34425  Sticky Note Big News for VDRM!! MegaVerde 02/07/18 11:54:52 AM
#13415  Sticky Note EVERYBODY: Get back and stay ON-TOPIC here. The topic IH Geek [Dave] 03/05/17 10:10:04 AM
#37699   Bottom is in. This just touched last years whatarush12 05/27/18 03:36:32 PM
#37697   The problem with that is I have zero zombywolf 05/26/18 07:55:47 PM
#37696   Z, if you picked up the phone and whatarush12 05/26/18 07:52:23 PM
#37695   W, they have to stop pumping deals, then zombywolf 05/26/18 07:41:04 PM
#37694   Bought 100,000 shares more today @ 0.007/sh. Next thiefscamfraud 05/26/18 03:36:32 AM
#37693   Patents? Is there even one published patent PhenixBleu 05/25/18 11:49:18 PM
#37692   They really haven't done any advertising freestock 05/25/18 09:41:45 PM
#37691   Also note the trip to india and more freestock 05/25/18 08:53:56 PM
#37690   One Key Paragraph from the report filed yesterday Here Today 05/25/18 08:17:44 PM
#37689   If you read that section of the 10Q hghscurry 05/25/18 05:38:13 PM
#37688   Mods maybe that three licenceing deals should freestock 05/25/18 04:13:18 PM
#37687   Excuse my ignorance again hghscurry but what does Teddy143 05/25/18 03:46:48 PM
#37686   That "D" word depends if that can stop Danorocket 05/25/18 03:46:30 PM
#37685   Next report maybe shows 300,000 $$$ in sales Budman33 05/25/18 03:38:53 PM
#37684   Excellent,,did not think these prices would be here Budman33 05/25/18 03:37:22 PM
#37683   Already in the party and have been. Next Danorocket 05/25/18 03:32:57 PM
#37682   By the time sales shows up on next Budman33 05/25/18 03:29:48 PM
#37681   I am going to hold off for a Danorocket 05/25/18 03:07:05 PM
#37680   Adding 3mill more to my stash next week! whatarush12 05/25/18 03:01:15 PM
#37679   Going to be an EPIC year for $VDRM whatarush12 05/25/18 02:59:49 PM
#37678   Agreed! It’s a screaming buy in the whatarush12 05/25/18 02:55:26 PM
#37677   Bought 250,000 today really believe that is a Budman33 05/25/18 02:41:24 PM
#37676   Late Friday PR would be nice! offset N2thecloud 05/25/18 02:10:36 PM
#37675   Just flushed the toad turd, lmao kennyt 335 05/25/18 02:07:11 PM
#37674   Down she goes......sounds like a toilet flushing. Lmao todd1975 05/25/18 02:00:23 PM
#37673   10Q confirmed 3 distribution/ licensing deals. Looking good hghscurry 05/25/18 01:53:24 PM
#37672   Down she goes.....lmfao todd1975 05/25/18 01:49:06 PM
#37671's not over until the fat lady sings, todd1975 05/25/18 01:45:02 PM
#37670   Hahahahaha, like stepping on a toad kennyt 335 05/25/18 01:41:35 PM
#37669's not over until the fat lady sings......or todd1975 05/25/18 01:38:52 PM
#37668   $VDRM Daily chart: lower highs + lower lows trading.jeff 05/25/18 12:57:14 PM
#37667   Todd I have a question for you what Trashman1957 05/25/18 12:49:49 PM
#37666   Quarterly FINS out.. whatarush12 05/25/18 12:23:22 PM
#37665   LOL whatarush12 05/25/18 12:03:09 PM
#37663   Lmao.....keep dreamin. Who would invest in a company todd1975 05/25/18 11:48:18 AM
#37660   Lol! Look at the intro.. all the facts whatarush12 05/25/18 10:41:05 AM
#37658   Know what you own, your opinion is just kennyt 335 05/25/18 09:21:13 AM
#37657   More blue sky nonsense. No facts just wishes billking1 05/25/18 09:17:35 AM
#37656   Good Morning VDRM! I'll bet everyone is looking SchlumpyStock-Picker 05/25/18 09:15:52 AM
#37655   Then what does this purport to be? Fasctrack 05/25/18 09:04:22 AM
#37654   What a sham.....lmao todd1975 05/25/18 07:56:20 AM
#37653   Please read their OTC Profile page and Disclosure PhenixBleu 05/25/18 06:11:24 AM
#37650   Tell me how it doesn’t meet requirements? It’s hghscurry 05/24/18 11:23:12 PM
#37647   Agreed Three! kennyt 335 05/24/18 08:54:02 PM
#37646   Ready, need to get this back in a Three2001 05/24/18 08:46:42 PM
#37642   I recommend reading the attorney letter to better PhenixBleu 05/24/18 06:41:15 PM
#37641   Any word from IR on the list of questions? Fasctrack 05/24/18 06:34:18 PM
#37640   You will see........this company has been pulling the todd1975 05/24/18 06:09:47 PM
#37639   LMAO! Keep trying Boogieflash 05/24/18 06:05:08 PM
#37638   In other words, for the last 12 months, nsomniyak 05/24/18 05:30:42 PM